CTLA4 and neoplasm: Tumor cells, along with other components of the TME, often express ligands for these checkpoints: CD80 for CTLA-4 and PD-L1 for PD-1, which helps tumors evade the immune system by suppressing T cell-mediated antitumor activity [97,98].